Low-dose blinatumomab for stubborn autoimmune brain inflammation
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a low dose of the drug blinatumomab to see if it can help adults with hard-to-treat autoimmune encephalitis or cerebellitis (brain inflammation caused by the immune system attacking the brain) who haven't gotten better with standard treatments. It aims to improve symptoms like memory loss, seizures, or coordination problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of antibody-positive autoimmune encephalitis or autoimmune cerebellitis.
- Your condition must be 'refractory,' meaning you've tried at least one round of first-line treatments (like steroids, IVIG, or plasma exchange) more than 6 weeks ago, and you've had additional immunotherapy (like rituximab or other drugs) for at least 2 months without improvement in your symptoms.
- Your disability level must be severe, with a modified Rankin Scale score greater than 3 (unable to walk or care for yourself) for at least 24 hours at the start of the study.
- You must not have other serious health issues like active infections, certain heart problems, low blood cell counts, or a history of cancer (except for specific, treated skin or ovarian tumors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Blinatumomab for people with myasthenia gravis that hasn't improved with standard treatments. It aims to see if the drug can help reduce muscle weakness and daily symptoms.
This trial studies giving medicine into the spinal fluid (intrathecal chemotherapy) to lower the risk of brain/nerve side effects from blinatumomab. It’s for adults with certain types of B-cell acute lymphoblastic leukemia (ALL) who are starting their first cycle.
This trial tests a new drug called blinatumomab for people with refractory myasthenia gravis (MG) that hasn't improved with standard treatments. It aims to see if the drug can help control muscle weakness and improve quality of life.
This trial tests a drug called blinatumomab for children with active lupus that hasn't improved with standard treatments. It aims to see if this immunotherapy can help calm the immune system and reduce lupus activity.
This trial tests a drug called blinatumomab for people with B-ALL whose leukemia has come back at a very low level (detected only by sensitive testing) after a stem cell transplant. The goal is to see if blinatumomab can clear these remaining leukemia cells and prevent a full relapse.
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
Hear when a new Autoimmune Encephalitis (AE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.